Breaks Categories: Stock Spotlights

WednesdayNov 25, 2020 2:43 pm

BioMedNewsBreaks – Trxade Group Inc.’s (NASDAQ: MEDS) Platform Meets Today’s Demands Through Intelligent Design

Trxade Group NASDAQ: MEDS), an integrated drug-procurement, delivery and health care platform, is ideally situated as the global pandemic has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services. Trxade Group’s business model appears to aptly and effectively meet today’s demands, largely demonstrated by the company’s revenue growth that has far exceeded expectations. A recent article discusses intelligent design of the Trxade platform that meets current standards of care while prioritizing information flow to assist both patients and providers. The article reads, “The company’s artificial intelligence API…

Continue Reading

ThursdayNov 12, 2020 3:31 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid in clinical decision-making and lead to better health outcomes. A recent article discussing growing opportunity in this sector reads, “The National Cancer Institute (‘NCI’) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of…

Continue Reading

MondayOct 19, 2020 12:21 pm

BioMedNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1…

Continue Reading

ThursdayOct 15, 2020 1:58 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books

Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of stable and soluble formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. Under the contract, Soluble Biotech will provide its expertise in protein expression and solubility studies. A recent article discussing this quotes Soluble Biotech founder Dr. Larry DeLucas. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” Dr. DeLucas stated. “We quadrupled our laboratory and…

Continue Reading

WednesdayOct 07, 2020 2:46 pm

BioMedNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Based out of South San Francisco, California, the “Birthplace of Biotechnology,” VistaGen is headquartered among the largest cluster of biotechnology companies in the world. A recent article discussing the company reads, “VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of…

Continue Reading

FridayOct 02, 2020 1:07 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (https://ibn.fm/Y9fBZ). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 tumors in an effort to personalize cancer therapies and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Collins addressed this powerful work and his longtime passion during the interview titled, “Can We Cure Cancer with Artificial Intelligence?” “The last 20 years of…

Continue Reading

FridayOct 02, 2020 12:46 pm

BioMedNewsBreaks – 180 Life Sciences Corp. Setting the Stage for Success in Bringing Novel Products to Market

180 Life Sciences, a clinical-stage biotechnology company, is focused on research to solve one of the world’s most significant drivers of disease – inflammation. The company currently has three programs for the development of novel drugs in the areas of fibrosis and anti-TNF, inflammatory pain and ulcerative colitis in ex-smokers. A recent article discusses the company’s strategy to expedite the path to market. The piece reads, “180 Life Sciences has mitigated the risks of its drug development through multiple programs at various stages of development. The company is actively decreasing costs and expediting the time to market by using grant…

Continue Reading

FridaySep 25, 2020 2:45 pm

BioMedNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. The company is advancing on this front as discussed by a recent article that reads, “180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are…

Continue Reading

TuesdaySep 22, 2020 5:03 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move forward with clinical trials in Poland. This move comes after sub-licensee WPD Pharmaceuticals Inc. has identified a contract research organization — Worldwide Clinical Trials — to coordinate and supervise Phase 1 and Phase 2 trials in the European country (http://ibn.fm/iFYph). A recent article discussing this reads, “Berubicin is proposed for the treatment of glioblastoma multiforme (‘GBM’), an aggressive and incurable form of brain cancer. Berubicin also…

Continue Reading

FridaySep 18, 2020 1:12 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven models designed to predict drug response and patient outcome of individual tumors. The company is able to do that because it relies on POAI’s tumor inventory, one of the largest in the world. POAI is a leader in working with oncologists in offering a functional precision medicine approach to treating cancer. Key information provided by Predictive Oncology can improve a patient’s odds in the fight against…

Continue Reading